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Emerging  evidence  suggests  that  the  basis  for  variation  in  late‐life mobility  is  attributable,  in part,  to  genetic
factors,  which  may  become  increasingly  important  with  age.  Our  objective  was  to  systematically  assess  the
contribution of genetic variation to gait speed  in older  individuals. We conducted a meta‐analysis of gait speed
GWASs in 31,478 older adults from 17 cohorts of the CHARGE consortium, and validated our results in 2,588 older
adults  from  4  independent  studies.  We  followed  our  initial  discoveries  with  network  and  eQTL  analysis  of
candidate signals in tissues. The meta‐analysis resulted in a list of 536 suggestive genome wide significant SNPs in
or near 69 genes. Further interrogation with  Pathway  Analysis  placed  gait  speed  as  a  polygenic  complex  trait 
in  five  major  networks.  Subsequent  eQTL  analysis  revealed  several  SNPs  significantly  associated  with  the
expression of PRSS16, WDSUB1 and PTPRT, which in addition to the  meta‐analysis  and  pathway  suggested  that 









Despite promising results from candidate gene studies, a 
systematic and comprehensive examination of genetic 
determinants of gait speed in a large sample of older 
adults has been lacking. Furthermore, previous study 
samples have been too small to detect the expected 
modest genetic effects especially in such complex and 
polygenic encoded traits. To address these limitations, 
we conducted a meta-analysis of GWAS of gait speed 
in 31,478 older adults and validate our candidate signal 
in a cohort of 2588 older adults. Close to 600 candidate 
genetic variants have been linked to gait speed. Such 
efforts have provided us with an increased knowledge 
of the biological systems which impact on gait speed; 
this may contribute to improved treatment strategies and 




Gait speed has been described as the “sixth vital sign” 
because it is a core indicator of health and function in 
aging and disease [1]. Decline in gait speed is 
ubiquitous with aging in both men and women [2]. Gait 
speed is used to establish thresholds in community 
based activities, such as crossing a street [3, 4] or 
ambulating [5-7]. Slow gait speed is a consistent risk 
factor for disability, cognitive impairment, 
institutionalization, falls, hospitalization and mortality 
[8-10]. Improvement in gait speed is associated with 
better function and survival. 
 
Many genetic and non-genetic factors (environment and 
disease) are likely to affect quantitative complex traits 
such as gait speed. There are individual differences in 
rates of decline in physical function, and genetic 
epidemiological studies provide a method for 
decomposing that variance into genetic and 
environmental sources. Twin studies suggest that 
genetic factors account for 15-51% of the variance of 
gait speed in older adults [11, 12]. Moreover, the 
contribution of genetic factors may increase with age [2, 
11, 13-15]. Offspring of parents with exceptional 
longevity have better physical function and gait speed in 
age-specific comparisons to other individuals of 
comparable age and other characteristics [16, 17]. 
Effective gait requires the integration of many 
physiological systems, including the central and 








motor program, the musculoskeletal system that moves 
and supports the body, and the cardio-pulmonary 
function that provides perfusion of adequate nutrients 
and oxygen to all of the integrated parts. All these 
physiological systems can be affected by genetic 
variation. Given the many pathways that may contribute 
to gait impairment, effect sizes of individual genetic 
variants are expected to be limited.  
 
Previous candidate gene studies have implicated several 
loci as relevant to gait speed. Single nucleotide 
polymorphisms (SNP) in the Angiotensin-Converting 
Enzyme (ACE) gene have been linked to better mobility 
response to exercise. The R577X polymorphism in the 
alpha-actinin-3 encoding gene (ACTN3) was associated 
with elite athletic performance, and muscle strength and 
power in the general population, especially in women 
[18]. There is evidence that ACE I/D and ACTN3 
R577X polymorphisms, individually or in combination, 
have a significant influence on mobility and gait speed 
phenotypes in older women [19, 20]. Catechol-O-
methyltransferase (COMT) polymorphisms have been 
associated with cognitive functions and gait speed [21]. 
The Met (158) Val polymorphism in COMT was linked 
to faster gait speed in older adults [21]. In addition, 
apolipoprotein E (APOE) genetic variation has been 
shown to influence the risk of gait speed decline [22-
24]. Despite these promising results from candidate 
gene studies, a systematic and comprehensive 
examination of genetic determinants of gait speed in a 
large sample of older adults has been lacking. 
Furthermore, previous study samples have been too 
small to detect the expected modest genetic effects [25] 
especially in such complex and polygenic encoded traits 
[26].  
 
To address these limitations, we conducted a meta-
analysis of GWAS studies of gait speed in 31,478 older 
adults from the Cohorts for Heart and Aging Research 
in Genomic Epidemiology (CHARGE) consortium. We 
then tested our findings in a validation cohort of 2588 




Gait speed is considered a marker of health and fitness 
in aging. Slow gait in older adults is associated with 
increased risk of multiple adverse events including loss 
of independence, increased risk of disability, falls [27, 
genetic  effects  on  gait  speed may  occur  through  synaptic  function  and  neuronal  development  pathways. No
genome‐wide significant signals for gait speed were identified from this moderately large sample of older adults,
suggesting  that more  refined physical  function phenotypes will be needed  to  identify  the genetic basis of gait
speed in aging.  
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28], progression of age-related disease including 
dementia [29] and death [9]. Slowing of gait 
is multifactorial with major contributions from 
potentially modifiable risk factors such as physical 
inactivity, cognitive impairment, muscle weakness, 
pain, poor vision, falls and obesity [30]. Gait speed 
was timed over fixed distance, and reported in m/sec 
units.  
 
In a meta-analysis of 31,478 subjects from 17 cohorts 
(Table 1, Supplementary Text) with ~2.5M imputed 
SNPs (Supplementary Table 1) 536 SNPs (202 were 
independent (LD, r2 < 0.8) based on the HaploReg tool 
[31]) with p< 1×10−4 of which 88 (48 were independent 
signals) had a p-value less than 1×10−5 and one SNP 
attained a p-value of less than p< 1×10−6 (Table 2, 
Supplementary Table 2). The Q-Q plot (Supplementary 
Figure 1) did not provide evidence of inflation of test 
statistics. The Manhattan plot (Figure 1), highlighted 2 
regions on chromosome 6 with high LD and suggestive 
association with gait speed (Regional plots [32] are 
displayed in Figure 2). These suggestive regions were 
further interrogated. Although none of the analyzed 

































was present in the top ten (POM121L2), and 7 other 
genes (CEP112, PHACTR1, CNTN5, PTPRT, FHOD3, 
ADAMTS18, PRIM2) were highlighted based on the 
presence of SNPs with suggestive significant 
associations (p<0.0001) as well as low recombination 
rate and linkage disequilibrium r2 >0.8 which may 
indicate significant signals in the segment (Figure 2, 
Supplementary Table 2, Supplementary Figure 2). The 
536 suggestive SNPs (p< 1×10−4 in the screening group) 
were tested for validation in four additional cohorts, 
GENOA, LLS, MrOSGBG and MrOSMalmo (2588 
subjects). Among the top 10 SNPs (six independent) 
only three exceeded nominal significance which slightly 
improved the combined meta-analysis significance for 
HLA-DPB1 SNPs (rs9501255, rs7763822 & 
rs3749985), however genome-wide levels of signifi-
cance were not attained (Table 2).      
 
Candidate gene approach 
 
None of the imputed variants previously reported as gait 
speed candidate genes such as ACE, ACTN3, COMT 
and APOE reached a nominally significant (p<0.05) 


































 Cohort Age, y %Female N with gait and GWAS Gait  protocol 
Screening AGES  >65 58.9 3,166 6 meter walk 
ARIC >60 59.5 445 7.6 meter walk 
BLSA >60 49.5 334 6 meter walk 
CHS  ≥65 60.9 3,184 4.6 meter walk 
FHS  >65 56.1 2,384 4 meter walk 
HABC >70 47.1 1,482 6 meter walk 
HRS >65 56.4 5,073 2.5 meter walk 
InCHIANTI > 60 55.8 898 4 meter walk 
LBC1921 77-80 58.4 510 6 meter walk 
LBC1936 67-71 49.5 1,001 6 meter walk 
MrOS ≥65 None 4,643 6 meter walk 
ROSMAP >60 69.2 1,646 2.5 meter walk 
RS-I >55 53  706 6 meter walk 
RS-II >55 51.8  813 6 meter walk 
RS-III >45 56.0  1,392 6 meter walk 
SOF ≥65 100 3,441 6 meter walk 
TASCOG >60 42 360 6 meter walk 
Total Screening  31,478  
Validation 
GENOA >60 55 471 7.6 meter walk 
LLS >60 47.2 235 4 meter walk 
MrOSGBG >69 None 960 6 meter walk 
MrOSMalmo >69 None 922 6 meter walk 
Total Validation  2,588  

















































































































Figure  1.  Manhattan  plot  of  meta‐analysis  of  genome  wide  association  studies  of  gait  speed  for  ~2.5  million
genotype and imputed SNPs. The blue line indicates the threshold used to select the 536 suggestive genome wide significant SNPs.
Table 2. Top 10 association meta‐analysis results for gait speed
      Screening Set (n=31,478) Validation Set (n=2,588) Screening + Validation 
Set (n=34,066) 
SNP Chr.:Position E/NE Allele 
F E 




Beta (SE) P HetPVal Beta (SE) P Beta (SE) P  
rs17527406 6:33709545 C/G 0.016 UQCC2(MNF1) intron 0.040(0.007) 5.22E-7 0.2669 0.014(0.032) 0.65 0.037(0.007) 6.883e-7
rs9501255* 6:33087321 T/C 0.038 HLA-DPB1 3’ UTR 0.023(0.005) 1.53e-6 0.5853 0.048(0.023) 0.04 0.024(0.005) 3.326e-7
rs7763822* 6:33092651 T/C 0.038 HLA-DPB1 3 0.023(0.005) 1.54e-6 0.5704 0.047(0.023) 0.04 0.024(0.005) 3.440e-7
rs3749985* 6:33086656 C/G 0.038 HLA-DPB1 3’ UTR 0.023(0.005) 1.55e-6 0.5856 0.048(0.023) 0.04 0.024(0.005) 3.385e-7
rs7746199# 6:27293545 C/T 0.166 POM121L2 15 0.011(0.002) 1.58E-6 0.9658 0.011(0.008) 0.19 0.011(0.002) 7.125e-7
rs12155739 8:102084750 C/T 0.030 NCALD intron -0.041(0.008) 2.04E-6 0.2076 -0.024(0.032) 0.45 -0.039(0.008) 1.858e-6
rs3800318# 6:27295862 A/T 0.830 POM121L2 13 -0.011(0.002) 2.07E-6 0.966 -0.011(0.008) 0.20 -0.011(0.002) 9.686e-7
rs13211166 6:27298161 A/T 0.190 POM121L2 11 0.011(0.002) 2.12E-6 0.9688 0.010(0.009) 0.24 0.010(0.002) 1.136e-6
rs9403969 6:148622038 T/G 0.737 SASH1 70 0.009(0.002) 2.34e-6 0.4004 0.005(0.007) 0.50 0.009(0.002) 2.351e-6
rs16897515# 6:27310241 A/C 0.161 POM121L2 missense 0.011(0.002) 2.41E-6 0.9505 0.007(0.009) 0.42 0.010(0.002) 2.080e-6
*First gene segment, #second gene segment. E/NE‐Effect‐, Non‐Effect allele; F E‐Frequency of Effect Allele; Δ‐distance to proximal gene;  
HetPVal‐ Heterogeneity P Value. 











































































































































































































































































Pathway analysis  
 
We used the 536 suggestive SNPs to generate the 
network analysis, in which 283 SNPs representing 68 
genes (Supplementary Table 4) were located in both the 
IPA dataset and the SeattleSeqAnnotation141 for SNP 
annotation (the remaining 253SNPs did not map to a 
gene). Among the genes having the highest number of 
defining SNPs, were CEP112 (38 SNPs), PHACTR1 
(23 SNPs), CNTN5 (19 SNPs), PTPRT (18 SNPs), 
FHOD3 (17 SNPs), ADAMTS18 (12 SNPs) and PRIM2 
(11 SNPs). The vast majority of these genes’ products 
are located in the cytoplasm and plasma membrane 
while the rest are in the nucleus, extracellular space and 
other cellular spaces. Ten types of protein actions 
(enzyme, transporter, phosphatase, transcription 
regulator, kinase, ion channel, transmembrane receptor, 







































tor and peptidase) are enumerated in Supplementary 
Table 5. Five of them serve as a biomarker for 
diagnosis, disease progression, prognosis, and 
unspecified application and five of them were targets 
for drug development including PRIM2, GABRA1, LYN, 
PRKCE and SCN11A. Five major putative disease and 
function networks were established using the candidate 
genes (based on the IPA software analysis significance 
classification) and were classified accordingly to cancer, 
gastrointestinal disease, organismal injury and 
abnormalities, neurological disease, cell and tissue 
morphology, cellular function, development and 
maintenance, amino acid metabolism, small molecule 
biochemistry, gene expression, cell-to-cell signaling and 
interaction, nervous system development and function, 
cellular assembly and organization. Seven genes were 
not mapped to any network (see Figure 3, 















































































































































































































































































By querying a large collection of eQTL results (listed in 
Supplementary Text), we obtained a long list of 
possible SNP relationships with gene expression 
(Supplementary Table 7). We also identified the 
strongest eQTL SNP for each particular transcript in 
each study. Those SNPs with low p-values (for 
association with gene expression, p<10-8) and high LD 
(D'>0.9) with the functional variant, were picked as 
candidates of signal concordance between the eQTL 
signals and gait speed signal. Following this analysis, 
several transcripts including PRSS16 and WDSUB1 
were highlighted (Supplementary Table 7). We also 
observed a relationship between a SNP and PTPRT 
expression (in liver tissue), which in addition to the 
meta-analysis and pathway analysis emphasized its 
potential functional link through its synaptic function 
and neuronal development, both of which may 
contribute to [33] gait speed. By emphasizing a strong 
relationship of the best eQTL with our queried SNPs, 
we likely underreport SNP-expression relationships due 
to missing LD information and the inability to project 

































Applying HaploReg v4.1 analysis to the 536 variants 
resulted in 9 categories (Supplementary Table 8): 
miscRNA (1 variant); snoRNA (2 variants); microRNA 
(4 variants); snRNA (9 variants); pseudogenes (14 
variants); sequencing in progress (43 variants); LINC 
RNA (86 variants); and 372 variants within protein 
coding genes. In addition, some variants annotate to the 
same gene resulting in a total of 139 genes (protein-
coding or non-coding). Of those genes, 6 are 
exceptionally long, containing over a million base-pairs, 
the longest of which is PTPRD coded by 2298477bp. 
The shortest genes are the ones coding for micro 
(MIR3143) or small nuclear (U7) RNAs at 63bp each. 
There is only partial information regarding the 
chromatin state of each variant. However, from the 
information gathered in the analysis we observed 14 
transcription start sites and 245 enhancers 




In this genome-wide association study of gait speed in 
31,478 adults ages 60 and older from 17 different 
cohorts in the USA, Europe and Australia and 2,588 
Figure 3. Ingenuity pathway analysis of genes associated with gait speed. Genes are represented as
nodes;  solid  lines  indicate direct‐  and hatched  lines  indirect‐  interaction. Gene  functions  are  color‐coded  as
follows: Red= other, Navy Blue =Group/Complex, Yellow= Enzyme, Turquoise= transcription regulator, Brown=
Ion  Channel,  Orange=  Phosphatase,  Purple  =  Kinase,  Magenta=  Transporter,  Beige=chemical‐endogenous
mammalian, Hunter Green (Dark Green) = Growth factor, light Green= Transmembrane Receptor, Light Purple=
Translation Regulator, Olive Green=Ligand‐dependent nuclear receptor, Bright green= Peptidase. 
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individuals in four validation cohorts, we did not 
discover any genome-wide significant association with 
gait speed nor did we confirm gait speed associations 
with previously reported candidate genes (i.e. ACE, 
ACTN3, COMT and APOE) (Supplementary Table 3). 
However, our analyses revealed some potentially 
relevant SNPs that could be targeted for further analyses 
regarding their associations with gait speed. 
 
Our results shed light on several candidate genetic 
polymorphisms that did not achieve genome wide 
significance but which had multiple signals on the gene 
segment, an observation that supported the association 
with the trait of interest. In addition, these SNPs map to 
genes that were either linked to physiologic functions 
expected to influence gait speed (such as neuromuscular 
function, cardiac function and muscle health or brain 
function) ADAMTS18, a gene associated with bone 
mineral density, could be associated with gait speed if 
individuals with variants in this gene had suffered from 
fracture leading to slowing of gait [34]. In functional 
studies ADAMTS18 levels were significantly lower in 
subjects with non-healing skeletal fractures compared to 
normal subjects [35]. POM121L2 - an ion transport 
gene [36] - was listed in the top ten meta-analysis genes 
with four variants, making it a potential candidate for 
our study.  This gene has been linked to schizophrenia, 
[37], suggesting a potential brain-related association 
with gait speed. One of the top candidates in our 
analysis was UQCC2 (also known as M19 or MNF1), a 
mitochondrial membrane protein that regulates skeletal 
muscle differentiation and insulin secretion [38]. 
Although UQCC2 function has a clear link to gait 
speed, the fact that in this study only one SNP found 
within UQCC2 demonstrated suggestive significance, 
which provides less confidence of a true association. 
NCALD, a calcium-binding protein, has been associated 
with diabetic nephropathy [39]. The region that was 
highlighted next to SASH1, a tumor suppressor gene, 
has multiple signals associated with gait speed. 
However, there is a high recombination rate between 
this region and the candidate gene (Figure 2), 
suggesting a higher dissociation between the gene and 
the signaled region. The last candidate from the top 10 
SNP association list is HLA-DPB1, an immune response 
gene that has been linked to rheumatoid and 
inflammatory myopathies [40, 41]. Interestingly, one of 
its variants (rs7763822) was indicated in systemic 
sclerosis susceptibility in Korean subjects [42] 
suggesting a pleiotropic effect. 
 
CEP112 involved in proper cell cycle progression [43] 
was not listed among the top 10 SNPs (Table 2) 
however its clear dominancy (38 SNPs) among the 536 
suggestive SNPs make it an attractive candidate for 
further functional association studies with gait speed. 
Similar to CEP112 variants, PHACTR1 regulates 
cardiac α-actin isoform ratio [44] and actomyosin 
assembly [45]; CNTN5 is associated with neuron 
function [46]; PTPRT regulates synaptic function and 
neuronal development [33] and serves as a genuine 
susceptibility locus for rheumatoid arthritis[33]; 
FHOD3, is a key regulator in the cardiac muscle [47] 
and sarcomere organization in striated muscle cells 
[48]; and PRIM2 is involved in DNA replication and 
transcription and is crucial for normal growth and 
development [49]. This list of genes repeatedly 
implicates associated signals that are important for 
neuromuscular function, cardiac function and muscle 
health, which could reasonably contribute to the 
complex trait of gait speed. 
 
A second tier of locus with repetitive signals established 
among the 536 suggestive SNPs included PDZN3, 
which is implicated in muscle function and regeneration 
[50-52], CACNG3, a voltage-dependent calcium 
channel subunit [53] that was previously linked to 
ataxic phenotype in mice [54], ASTN2 that functions in 
neuronal migration [55] and that was associated with 
hip osteoarthritis susceptibility [56], SIM1 involved in 
coordinating muscle activity and generating rhythmic 
activity [57]  and also associated with obesity [58], and 
MDGA2, which is required for proper development of 
cranial motoneuron subtypes [59].  
 
The eQTL analysis (various tissues and cell types, listed 
in Supplementary Text) of the 536 suggestive SNPs 
reported a couple of candidate genes such as PRSS16, a 
gene encoding serine protease expressed exclusively in 
the thymus. PRSS16 was associated with exercise [60] 
and was linked to COMT (a candidate gene for gait 
speed (20)). Both are regulated by ZNF804a [61]. This 
link between the two genes (PRSS16 and COMT) may 
support our gait speed association results.  Another 
candidate gene from our eQTL analysis was WDSUB1 a 
U-box ubiquitin ligases encoded protein which was 
associated with sudden cardiac death [62]. A link with 
cardiovascular diseases may indicate a potential 
cardiovascular effect on gait speed. The last candidate 
in this analysis is PTPRT, a gene that regulates synaptic 
function and neuronal development. It is possible that 
its link to gait speed (operates  through its role in 
diabetes [63]). The fact that it was present in all three 
sets of analysis results may suggest a stronger candidate 
for further analysis. 
 
The lead motif of the network analysis in all 5 disease 
networks was “cellular function”, however, the 
candidate SNPs from the multiple analysis strategies 
strongly suggested links to bone, skeleton, muscle and 
brain, incorporating development, structure and 
function. While our SNP associations did not achieve 
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genome wide significance, we believe that we 
demonstrated a potential link to gait speed. To exclude 
false positive signals, these associations should be 
pursued further in controlled experiments as well as 
animal models, which will increase our understanding 
of the biology of gait speed deterioration with aging. 
Such efforts would provide us with an increased 
knowledge of the biological systems which impact on 
gait speed; this may contribute to improved treatment 
strategies and drug development to promote aging with 
grace.  
 
This study did not provide conclusive evidence for the 
genetics contributing to gait speed. While the large 
sample is a strength (and we have the power to detect 
smaller effects), the observed associations suggest that 
an even larger sample is required to establish genetic 
contributions to the gait speed phenotype. The 
individual effects of common SNPs for complex traits 
such as gait speed are expected to be very small. From 
studies of other polygenic complex traits, it has been 
observed that the number of discovered variants is 
strongly correlated with experimental sample size [64]. 
Another potential explanation why we did not observe 
genome wide significant associations is that there are 
many potential pathways that contribute to gait speed, 
including nervous system function (neuromuscular, 
central nervous system), musculoskeletal conditions 
such as sarcopenia and osteoarthritis, cardiovascular 
disease, visual function, psychological factors and other 
contributors.  This complexity of phenotype may make 
it difficult to discover associations.  Phenotype 
refinement may be a future approach to explore. 
 
In summary, the lack of genome-wide significant 
signals from this moderately large sample of older 
adults suggests that larger samples (or study to sub-
classify the gait speed phenotype) will be needed to 
identify SNP-based associations. Also, it may suggest 
that downstream mechanisms are more likely to make 
more important contributions to gait speed. Gait speed 
is a complex phenotype with many potential 
contributors; it is not unsurprising that it should be 
governed by multiple genes. However, we were able to 
use network analyses to define some potential networks 
of genes that might be of relevance for this phenotype.  
Future studies may be best positioned to focus on one 
network in more detail and to examine gene-environment 






The Aging and Longevity Working Group of the 
CHARGE Consortium [65, 66], was formed to facilitate 
genome-wide association study meta-analyses of age 
associated diseases and phenotypes among multiple 
large and well-phenotyped cohorts of older individuals 




A combined cohort of 31,478 subjects age 60 years and 
older with timed walks constituted our discovery 
sample (Table 1). Timed walk at usual pace was 
converted to gait speed (m/s) to harmonize the 
phenotype across cohorts. Participants of the following 
17 European descendent cohorts were included 
(Supplementary Material):  
 
The Age, Gene/Environment Susceptibility-Reykjavik 
(AGES), The Atherosclerosis Risk in Communities 
(ARIC), Baltimore Longitudinal study on Aging 
(BLSA), Cardiovascular Health Study (CHS), 
Framingham Heart Study (FHS), Health, Aging, and 
Body Composition Study (HABC), Health and 
Retirement Study (HRS), Invecchiare in Chianti 
(InCHIANTI), Lothian Birth Cohorts 1921 (LBC1921) 
and 1936 (LBC1936), Osteoporotic Fractures in Men 
Study (MrOS), The Religious Orders Study and Rush 
Memory and Aging Project (ROSMAP), Rotterdam 
Study (RS-I, -II, -III), Study of Osteoporotic Fractures 
(SOF), Tasmanian Study of Cognition and Gait 
(TASCOG)  (Table 1, Supplementary Text). All 
participants with gait speed assessments including 
participants who were able to walk with assistance of a 
cane were included in this analysis. Exclusion criteria 
included missing gait assessments and inability to walk 




The validation cohort consisted of 2,588 subjects (>60 
years) from the Genetic Epidemiology Network of 
Arteriopathy (GENOA), Leiden Longevity Study 
(LLS), Osteoporotic Fractures in Men Study (MrOS) 
Sweden, Malmö[MrOSMalmo] and Gothenburg 
[MrOSGBG] studies (Table 1, Supplement text). 
Together these cohorts reach the minimum number of 
subjects required for sufficient statistical power (Our 
power calculation shows that given a fixed sample size 
(n=2500) our analysis will have >80% power to detect 
MAF=0.01, alpha<0.0001) to validate significant 
signal(s) from the screening cohort using the same 
harmonized gait speed phenotype. Results from the 
screening and validation cohorts were meta-analyzed. 
 
Phenotype definition  
 
The different methods of assessing gait speed in 
individual cohorts are described in Table 1 and 
www.aging‐us.com  222  AGING (Albany NY) 
Supplementary Text. Variability in the methods of 
assessing gait speed in the participating cohorts 
included differences in distance walked (8 to 25 feet) 
and measurement techniques (instrumented walkway 
versus stopwatch).  Previous reports including 4 cohorts 
from this report (CHS, HABC, InCHIANTI and SOF) 
have suggested that there is a high correlation (r2>0.9) 
between the different methods of measuring gait speed 
[9, 24, 67].  The mean overall gait speed was 1.13± 0.25 
m/sec, and varied from 0.66 ± 0.16 m/sec to 1.66 ± 0.41 
m/sec in the individual cohorts (Supplementary Table 9, 




A structured, pre-specified analytical plan was applied 
to each of the 17 cohorts included in the screening 
sample. Genome-wide analysis of imputed genotypes, 
summarized in Supplementary Text, were conducted in 
each cohort.  Imputation (using either BimBam or 
MACH) resulted in approximately 2.5 million HapMap 
SNPs being available for analysis. Imputation details, 
QC and SNP count per cohort can be found in 
Supplementary Text and Supplementary Table 1. 
Exclusion criteria for SNP in each of the 21 cohorts 
(screening and validation) included: 1) minor allele 
frequency (MAF) < 0.005); 2) imputation quality (R2 or 
oevar_imp < 0.3); and for the meta-analysis, SNPs with 




Multiple linear regression of imputed SNP dosages on 
gait speed was performed using an additive model, i.e. 
as a count of the number of variant alleles present (1 
degree of freedom). Sex-combined analysis was 
performed. Adjustment for age (at time of exam), sex, 
study site (for cohorts with multiple sites), principal 
components to control for population stratification, 
height, and presence of osteoarthritis (yes/no) if 
available were included. For cohorts with osteoarthritis 
data available, the analysis was done excluding 
participants with osteoarthritis (Supplementary Text and 




Inverse variance weighted meta-analysis was performed 
on summary statistics of the cohort-level association 
analyses. Meta-analysis of gait speed (Screening and 
validation cohorts were analyzed separately as well as 
together (joint meta-analysis)) was performed using 
METAL [68] with a fixed effects model of beta 
estimates and standard errors from each cohort. In 
addition, we applied heterogeneity  test  between studies  
(on both screening and validation cohorts) using 
METAL. A p-value threshold (Bonferroni-adjusted) of 





We assembled a list of 536 meta-analyzed SNPs 
(representing 69 genes) that were highly suggestively 
associated (p < 1 × 10−4) with gait speed. This list 
resulted in 67 candidate genes (Annotated by Ingenuity 
Pathway Analysis (IPA) and SeattleSeqAnnotation) 
being identified which were used in the IPA analysis 
(www.ingenuity.com). The resulting classification of 
networks, pathways, biological processes and molecular 
functions are represented in tables and graphic format 
(Figure 3, Supplementary Table 4, 5 and 6).  
 
Expression quantitative trait loci (eQTL) analysis  
 
We examined existing eQTL resources for the candidate 
suggestive list of 536 SNPs (p<10-4) to further explore 
their biological and functional relevance to gait speed 
(Supplementary Text). We queried these SNPs against 
an eQTL database (listed in Supplementary Text) 
containing eQTL results from over 100 studies across a 
wide range of tissues. A general overview of a subset of 
>50 eQTL studies has been published [69], with 
specific citations for the included datasets included in 
the Supplementary Material. 
 
Further we applied the HaploReg v4.1 annotation tool 
for TF analysis of 536 SNPs suggestively associated 
with gait speed. 
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